Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Patent
1995-11-03
1998-01-20
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
A61K 3821
Patent
active
057098530
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a novel pharmaceutical composition for atopic disease.
BACKGROUND ART
Atopic diseases is a generic name for allergic diseases which are developed by exposing to extrinsic allergens individuals who have a family factor of being easily sensitized by such allergens. Patients having the factors of this disease easily exhibit severe hypersensitivities by alimentary antigens and inhalants. The patients also easily experience abnormalities in autonomic nerves, endocrines and immunological systems, by extrinsic invasions such as fever, coldness, humidity, injury, infection, or by intrinsic stress such as a mental strain. More specifically, atopic dermatitis, extrinsic bronchial asthma, urticaria, allergic rhinitis, allergic enterogastritis and the like are considered as atopic diseases.
As drug therapy for atopic disease, at present, antihistaminics, steroids, bronchodilators and others are employed as symptomatic therapies.
Among them, steroids are used mainly, however, they have some problems in clinical use. That is, they require a long-term administration to exhibit their effects, and further, they have local and systemic side effects. Thus, a useful drug has been desired which can substitute for or support steroids, and, furthermore, can be used as a causal treatment.
Recently, it has been found that atopic diseases are caused by immunological abnormalities, and that, especially, an acceleration of IgE production is a main factor of the disease. Therefore, immunomodulators for immunological abnormality, such as levamisole, transfer factors, thymopentin-pentapeptide, and cyclosporin have been applied. On the other hand, interferon .gamma. and interferon .alpha. have been known to possess strong immunomodulatory effects, and it was reported that they.strongly inhibited production of IgE from lymphocytes (Pene J. et al., Proc. Nat. Acad. Sci. (USA), 1988; 85, 6880-4), production of interferon .gamma. was inhibited in local infiltrative lymphocytes associated with atopic dermatitis and asthma (J. Immunol., 1979; 123, 1788-94), and interferon .gamma. inhibited an enhancement of helper T2 lymphocytes (Gajewski TF et al., J. Immunol., 1988; 140, 4245-52). Thus, interferon .gamma. and interferon .alpha. have been used for treatment of atopic dermatitis and asthma, providing good results (Parkin JM et al., Br. Med. J., 1987; 294, 1185-6, Hanifin JM et al., J. Am. Acad. Dermatol., 1993; 28, 187-97, etc.). They have, however, not yet been applied to a practical use, because their results from clinical studies are not. constant, therapeutic effects are not continuous, the disease will recur in a short time after the end of the administration, and some side effects are associated with them in the case of long-term administration.
As mentioned above, a pharmaceutical composition for atopic diseases up to now has not yet been provided, which has a fast-acting property and a prolonged action with less side effects. The object of the present invention is to provide a novel pharmaceutical composition for atopic diseases which is more effective and able to overcome the defects of conventional drugs.
DISCLOSURE OF THE INVENTION
The present invention relates to a pharmaceutical composition for atopic diseases comprising interferon .beta. as an active ingredient.
BEST MODE FOR CARRYING OUT THE INVENTION
Interferon .beta. in accordance with the present invention may be a natural type, a product from chemical synthesis, or a product obtained by gene recombinant technique, and also may be a polypeptide having the active site structure of the above three types of interferon .beta. therein. Natural interferon .beta. produced by human diploid fibroblasts are preferably used in the present invention.
Natural interferon .beta. may be obtained as follows. Interferon .beta. producing cells, which have been cultured on the surface of glass, plastic, or a microcarrier of DEAE-dextran, etc. receive an induction treatment with synthetic double-stranded RNA such as Poly I:C, followed by
REFERENCES:
The Merck Index, 11Ed, No. 4892, Merck & Co., Inc., Rahway, N.J. 1989, p. 791.
Reinhold, Uwe, et al., "Systemic Interferon gamma treatment in severe atopic dermatitis," J. Am. Acad. Dermatol. 29(1), 58-63 (1993).
Pung, Yung-Hao, et al., "Use of interferons in atopic (IgE-mediated) diseases." Ann. Allergy 71, 234-38 (1993).
Johnson et al, Scientific American, 68, 73 (May 1994).
Iino Shiro
Kawashima Yoshiharu
Goldberg Jerome D.
Miller Austin R.
Toray Industries Inc.
LandOfFree
Method of treatment of atopic disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment of atopic disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment of atopic disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-723328